Anixa Biosciences Inc
ANIX3.280USD
-0.020-0.61%
Market hours （ET）Quotes delayed by 15 min
107.66MMarket Cap
LossP/E TTM
More Details of Anixa Biosciences Inc Company
Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
Anixa Biosciences Inc Info
Ticker SymbolANIX
Company nameAnixa Biosciences Inc
IPO dateOct 07, 1983
CEOKumar (Amit)
Number of employees5
Security typeOrdinary Share
Fiscal year-endOct 07
Address3150 Almaden Expy Ste 250
CitySAN JOSE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code95118
Phone14087089808
Websitehttps://www.anixa.com/
Ticker SymbolANIX
IPO dateOct 07, 1983
CEOKumar (Amit)
Company Executives of Anixa Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Amit Kumar, Ph.D.
Dr. Amit Kumar, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
610.49K
+5.27%
Ms. Emily Gottschalk
Ms. Emily Gottschalk
Independent Director
Independent Director
45.66K
--
Mr. Michael J. (Mike) Catelani
Mr. Michael J. (Mike) Catelani
President, Chief Financial Officer, Chief Operating Officer, Secretary
President, Chief Financial Officer, Chief Operating Officer, Secretary
44.50K
+26.38%
Mr. Lewis H. (Lew) Titterton, Jr.
Mr. Lewis H. (Lew) Titterton, Jr.
Lead Independent Director
Lead Independent Director
--
--
Dr. Arnold Baskies, M.D.
Dr. Arnold Baskies, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Amit Kumar, Ph.D.
Dr. Amit Kumar, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
610.49K
+5.27%
Ms. Emily Gottschalk
Ms. Emily Gottschalk
Independent Director
Independent Director
45.66K
--
Mr. Michael J. (Mike) Catelani
Mr. Michael J. (Mike) Catelani
President, Chief Financial Officer, Chief Operating Officer, Secretary
President, Chief Financial Officer, Chief Operating Officer, Secretary
44.50K
+26.38%
Mr. Lewis H. (Lew) Titterton, Jr.
Mr. Lewis H. (Lew) Titterton, Jr.
Lead Independent Director
Lead Independent Director
--
--
Dr. Arnold Baskies, M.D.
Dr. Arnold Baskies, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.32%
Titterton (Lewis H Jr)
2.94%
D.A. Davidson & Co.(Research)
1.87%
Kumar (Amit)
1.85%
Laird Norton Wealth Management
1.81%
Other
87.20%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.32%
Titterton (Lewis H Jr)
2.94%
D.A. Davidson & Co.(Research)
1.87%
Kumar (Amit)
1.85%
Laird Norton Wealth Management
1.81%
Other
87.20%
Shareholder Types
Shareholders
Proportion
Investment Advisor
9.11%
Individual Investor
5.45%
Research Firm
2.65%
Investment Advisor/Hedge Fund
2.38%
Private Equity
1.81%
Hedge Fund
0.70%
Insurance Company
0.03%
Other
77.86%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
111
5.50M
17.72%
--
2025Q3
116
5.51M
17.85%
+92.92K
2025Q2
115
5.42M
19.08%
-261.57K
2025Q1
112
5.69M
19.50%
-587.54K
2024Q4
110
5.90M
18.29%
+275.49K
2024Q3
99
5.63M
18.58%
+25.43K
2024Q2
100
5.60M
17.30%
+281.36K
2024Q1
103
5.34M
14.66%
+659.96K
2023Q4
101
4.46M
13.71%
+493.01K
2023Q3
97
3.97M
13.01%
+290.44K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
1.39M
4.23%
--
--
Jun 30, 2025
Titterton (Lewis H Jr)
953.33K
2.9%
+20.00K
+2.14%
Jul 31, 2025
D.A. Davidson & Co.(Research)
614.27K
1.87%
--
--
Jun 30, 2025
Kumar (Amit)
579.92K
1.76%
+10.00K
+1.75%
Jul 30, 2025
Laird Norton Wealth Management
617.24K
1.88%
-5.00K
-0.80%
Jun 30, 2025
UBS Financial Services, Inc.
505.29K
1.53%
-18.87K
-3.60%
Jun 30, 2025
Mission Wealth Management, LP
369.52K
1.12%
-100.00K
-21.30%
Jun 30, 2025
Geode Capital Management, L.L.C.
342.84K
1.04%
+2.57K
+0.76%
Jun 30, 2025
BofA Global Research (US)
210.31K
0.64%
+41.00
+0.02%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
152.94K
0.46%
-2.19K
-1.41%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Micro-Cap ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Anixa Biosciences Inc?
The top five shareholders of Anixa Biosciences Inc are:
The Vanguard Group, Inc. holds 1.39M shares, accounting for 4.23% of the total shares.
Titterton (Lewis H Jr) holds 953.33K shares, accounting for 2.90% of the total shares.
D.A. Davidson & Co.(Research) holds 614.27K shares, accounting for 1.87% of the total shares.
Kumar (Amit) holds 579.92K shares, accounting for 1.76% of the total shares.
Laird Norton Wealth Management holds 617.24K shares, accounting for 1.88% of the total shares.
The Vanguard Group, Inc. holds 1.39M shares, accounting for 4.23% of the total shares.
Titterton (Lewis H Jr) holds 953.33K shares, accounting for 2.90% of the total shares.
D.A. Davidson & Co.(Research) holds 614.27K shares, accounting for 1.87% of the total shares.
Kumar (Amit) holds 579.92K shares, accounting for 1.76% of the total shares.
Laird Norton Wealth Management holds 617.24K shares, accounting for 1.88% of the total shares.
What are the top three shareholder types of Anixa Biosciences Inc?
The top three shareholder types of Anixa Biosciences Inc are:
The Vanguard Group, Inc.
Titterton (Lewis H Jr)
D.A. Davidson & Co.(Research)
The Vanguard Group, Inc.
Titterton (Lewis H Jr)
D.A. Davidson & Co.(Research)
How many institutions hold shares of Anixa Biosciences Inc (ANIX)?
As of 2025Q4, 111 institutions hold shares of Anixa Biosciences Inc, with a combined market value of approximately 5.50M, accounting for 17.72% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.13%.
What is the biggest source of revenue for Anixa Biosciences Inc?
In --, the -- business generated the highest revenue for Anixa Biosciences Inc, amounting to -- and accounting for --% of total revenue.
